Opsin 3 serves as a potential therapeutic target for melanoma and inflammatory skin diseases
Opsin 3 May Offer New Path for Skin Disease Treatment
This narrative review explores the role of Opsin 3 (OPN3) in skin pathophysiology, including its involvement in UV damage, melanoma developm…
A protein called Opsin 3 may play a key role in how skin cells respond to UV damage, aging, and inflammation.
EMG biofeedback assisted pelvic floor training improves muscle strength and reduces incontinence severity
Biofeedback training shows some benefits for stress urinary incontinence
This meta-analysis of 1,045 women with stress urinary incontinence found that EMG-BF supported PFMT leads to a small reduction in incontinen…
Adding biofeedback to pelvic floor exercises may improve muscle strength and quality of life for women dealing with stress urinary incontine…
Extracellular vesicles offer immunomodulatory mechanisms and targeted delivery for potential precision therapies in rheumatoid arthritis
Tiny cell particles may offer new way to treat rheumatoid arthritis
This systematic review examines the role of extracellular vesicles, including exosomes and microvesicles, as vehicles for immunomodulation a…
Scientists are exploring tiny cell particles called extracellular vesicles as a potential new treatment for rheumatoid arthritis, but challe…
Comprehensive clinical reference system integrates etiology, diagnosis, and management for chronic pancreatitis complications
New Clinical Reference System for Managing Chronic Pancreatitis Complications
This narrative review synthesizes the etiology, diagnostic criteria, and management strategies for primary complications of chronic pancreat…
A new clinical reference system helps doctors identify and manage common complications like digestive issues and bone disease in patients wi…
Gut microbiota dysbiosis linked to osteoarthritis pathology in preclinical and human studies
Gut health may play a role in osteoarthritis joint pain
This narrative review synthesizes evidence linking gut microbiota dysbiosis to osteoarthritis. Human studies show OA-associated changes in m…
New research suggests that imbalances in gut bacteria could contribute to cartilage damage and inflammation in people with osteoarthritis.
Intestinal subepithelial myofibroblasts drive mucosal repair and pathological fibrosis in Inflammatory Bowel Disease
New Research Identifies Key Cells Driving Fibrosis in Inflammatory Bowel Disease
This narrative review explores the role of intestinal subepithelial myofibroblasts (ISEMFs) as central regulators of epithelial homeostasis …
Researchers have identified specific cells in the gut that drive scarring and tissue damage in people with inflammatory bowel disease.
FDA Approves Xeljanz XR (tofacitinib) for Multiple Inflammatory Conditions
FDA approves new arthritis and colitis drug Xeljanz XR for adults and children.
The FDA approved Xeljanz XR (tofacitinib) extended-release tablets for adult patients with moderately to severely active rheumatoid arthriti…
The FDA approved Xeljanz XR (tofacitinib) for adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative …
FDA Approves Xeljanz (tofacitinib) for Multiple Inflammatory Conditions
FDA approves new oral drug Xeljanz for arthritis and colitis.
The FDA approved Xeljanz (tofacitinib) tablets and Xeljanz XR extended-release tablets for adults with moderately to severely active rheumat…
The FDA approved Xeljanz (tofacitinib) for adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative col…
FDA Approves Xeljanz (tofacitinib) for Pediatric Psoriatic Arthritis and Juvenile Idiopathic Arthritis
FDA approves Xeljanz for children with arthritis conditions.
The FDA approved Xeljanz (tofacitinib) for pediatric patients 2 years and older with active psoriatic arthritis or polyarticular course juve…
The FDA approved Xeljanz for children ages 2 and older with psoriatic arthritis or juvenile idiopathic arthritis. This provides a new oral o…
Nafamostat mesylate reduces bleeding risk compared to citrate for anticoagulation during continuous renal replacement therapy
Nafamostat mesylate may lower bleeding risks during kidney dialysis
This systematic review and meta-analysis of 2,247 CRRT patient episodes found that nafamostat mesylate significantly reduced the risk of ble…
A new analysis suggests nafamostat mesylate could be a safer alternative for patients at high risk of bleeding during continuous renal repla…
Belimumab linked to higher remission and low disease activity rates in SLE without glucocorticoids
Trial shows belimumab improves remission rates for lupus patients
A post hoc analysis of phase III trials found that belimumab plus standard therapy led to higher rates of DORIS remission and LLDAS attainme…
A new analysis of clinical trials shows that the drug belimumab helps more people with lupus reach specific remission goals compared to a pl…
Evaluating Treat to Target Outcomes in Elderly and Young Rheumatoid Arthritis Patients
Treat-to-Target Strategy Shows Promise for Elderly Rheumatoid Arthritis
A multicenter trial confirms that elderly patients achieve similar clinical outcomes and safety profiles as younger cohorts under a standard…
A new study shows that elderly patients with rheumatoid arthritis can achieve similar results to younger patients using a standard treat-to-…